for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Windtree Therapeutics Inc

WINT.OQ

Latest Trade

2.30USD

Change

0.00(0.00%)

Volume

295

Today's Range

--

 - 

--

52 Week Range

2.08

 - 

10.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Windtree Therapeutics Reports Q4 Loss Per Share $0.44

March 29 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2020 FINANCIAL RESULTS AND PROVIDES KEY BUSINESS UPDATES.Q4 LOSS PER SHARE $0.44.AS OF DEC 30, 2020, CO REPORTED CASH, CASH EQUIVALENTS OF $16.9 MILLION.

Windtree Therapeutics Announces Proposed Public Offering Of Common Stock

March 22 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.WINDTREE THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING FOR CONTINUED ADVANCEMENT OF ITS PRODUCT CANDIDATE ISTAROXIME.

Windtree Therapeutics Reports Q3 Loss Per Share $0.54

Nov 16 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES KEY BUSINESS UPDATES.Q3 LOSS PER SHARE $0.54.AS OF SEPTEMBER 30, 2020, CO REPORTED CASH AND CASH EQUIVALENTS OF $22.4 MILLION.WILL BE ABLE TO FUND OPERATIONS THROUGH AT LEAST NEXT TWELVE MONTHS.

Windtree Says FDA Acceptance Of Ind Application For A Phase 2 Clinical Trial Studying Kl4 Surfactant In Acute Lung Injury In Adults With Covid-19

Sept 29 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR A PHASE 2 CLINICAL TRIAL STUDYING KL4 SURFACTANT IN ACUTE LUNG INJURY IN ADULTS WITH COVID-19.WINDTREE THERAPEUTICS INC - SEES POTENTIAL EXPANDED COVID-19 PROGRAM AS NEXT STEP.WINDTREE THERAPEUTICS INC - PLANS TO START INITIAL COVID-19 PHASE 2 STUDY WITHIN NEXT SEVERAL WEEKS.WINDTREE - IF INITIAL PHASE 2 STUDY RESULTS SHOW ADEQUATE SAFETY & EFFICACY UNDER COVID-19 PROGRAM, WOULD PLAN TO INITIATE 2 ADDITIONAL CLINICAL TRIALS.

Windtree Therapeutics Files For Mixed Shelf Of Upto $75 Mln - SEC Filing

Sept 17 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.

Windtree Appoints John Hamill As Chief Financial Officer

July 20 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE APPOINTS JOHN HAMILL AS CHIEF FINANCIAL OFFICER.WINDTREE APPOINTS JOHN HAMILL AS CHIEF FINANCIAL OFFICER.WINDTREE THERAPEUTICS INC - JOHN HAMILL IS REPLACING FORMER CFO, JOHN TATTORY.

Windtree Therapeutics Reports Pricing Of $20.0 Mln Public Offering

May 20 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS ANNOUNCES PRICING OF $20.0 MILLION PUBLIC OFFERING AND UPLISTING TO THE NASDAQ CAPITAL MARKET.WINDTREE THERAPEUTICS INC - PRICING OF PUBLIC OFFERING OF 2.8 MILLION UNITS AT A PRICE TO PUBLIC OF $7.25 PER UNIT.WINDTREE THERAPEUTICS INC - IN CONNECTION WITH OFFERING, ITS COMMON STOCK HAS BEEN APPROVED FOR LISTING ON NASDAQ CAPITAL MARKET.WINDTREE THERAPEUTICS INC - WILL BEGIN TRADING ON NASDAQ CAPITAL MARKET UNDER SYMBOL "WINT" ON MAY 20, 2020.

Windtree Therapeutics- Have Applied To List Common Stock On Nasdaq Capital Market, Or Nasdaq

Jan 27 (Reuters) - Windtree Therapeutics Inc <WINT.PK>::WINDTREE THERAPEUTICS INC - HAVE APPLIED TO LIST COMMON STOCK ON THE NASDAQ CAPITAL MARKET, OR NASDAQ, UNDER THE SYMBOL "WINT".

Windtree announces top-line results from aerosurf phase 2B clinical trial

June 29 (Reuters) - Windtree Therapeutics Inc <WINT.PK>::Windtree announces top-line results from aerosurf phase 2B clinical trial for the treatment of respiratory distress syndrome (RDS) in premature infants.

Windtree Therapeutics recieves $0.9 mln as part of NIH grant

May 22 (Reuters) - Windtree Therapeutics Inc <WINT.PK>:Windtree receives sbir grant in continued support of aerosurf® phase 2b clinical trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up